{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:16:33Z","timestamp":1790705793109,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["33\/16\/2019-TF\/R\/Rare\/BMS"],"award-info":[{"award-number":["33\/16\/2019-TF\/R\/Rare\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.msard.2025.106402","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T10:22:32Z","timestamp":1742466152000},"page":"106402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Clinico-investigational profile, relapse predictors and outcomes of pediatric patients with anti-myelin oligodendrocyte associated disorders: An experience from tertiary centre"],"prefix":"10.1016","volume":"97","author":[{"given":"Debjyoti","family":"Dhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7909-8124","authenticated-orcid":false,"given":"Subhajit","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra","family":"Kenchaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahammad Samim","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seetam","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraswati","family":"Nashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Santhoshkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Mahale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagaraj","family":"AR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya Dattatraya","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6473-4319","authenticated-orcid":false,"given":"Hansashree","family":"Padmanabha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106402_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-332542","article-title":"Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course","author":"Abdel-Mannan","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106402_bib0002","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1212\/WNL.98.18_supplement.3452","article-title":"MOGAD Atypical presentations in pediatric patients (P13-4.002)","volume":"98","author":"Adeseye","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106402_bib0003","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0004","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: part 5 \u2013 treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0006","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1212\/WNL.0000000000208149","article-title":"MOGAD presenting atypically with severely elevated ICP and meningoencephalitis: severe complicated hospital course followed by return to near baseline (P9-14.013)","volume":"102","author":"Camargo","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106402_bib0007","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.26731","article-title":"Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD?","volume":"94","author":"Chen","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0009","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: an observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0010","article-title":"Rare encephalitis-like presentation of a pediatric patient with dual positive aquaporin-4 and myelin oligodendrocyte antibodies: a case report with review of literature","volume":"26","author":"Dhar","year":"2023","journal-title":"Ann. India. Acad. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jocn.2023.10.003","article-title":"Tract-specific myelopathy in myelin oligodendrocyte associated disorder: a novel finding","volume":"118","author":"Dhar","year":"2023","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2025.106402_bib0012","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev. Med. Child. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103229","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: the difficulty of predicting relapses","volume":"56","author":"Epstein","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106402_bib0014","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(20)30432-4","article-title":"Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care","volume":"20","author":"Fadda","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3174\/ajnr.A8089","article-title":"Clinical and imaging findings in children with myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD): from presentation to relapse","volume":"45","author":"George","year":"2024","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2025.106402_bib0016","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"\u2018Leukodystrophy-like\u2019 phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev. Med. Child. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0017","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated Disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0018","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106402_bib0019","article-title":"Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106402_bib0020","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105130","article-title":"Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"81","author":"Martin","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106402_bib0022","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1055\/s-0043-1777002","article-title":"Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience","volume":"81","author":"Messias","year":"2023","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106402_bib0023","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00415-020-10300-z","article-title":"Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder","volume":"268","author":"Netravathi","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105497","article-title":"Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated disease in a diverse cohort of children: a single-center observational study","volume":"84","author":"Nguyen","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106402_bib0025","unstructured":"Prognostic Relevance of MOG Antibodies in Children with an Acquired Demyelinating Syndrome.; 2017."},{"key":"10.1016\/j.msard.2025.106402_bib0026","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pediatrneurol.2023.02.019","article-title":"Clinical and radiologic features among children with myelin oligodendrocyte glycoprotein antibody-associated myelitis","volume":"143","author":"Ren","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0027","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s10072-023-06686-z","article-title":"Clinical and radiological spectrum of anti-myelin oligodendrocyte glycoprotein (MOG) antibody encephalitis: single-center observational study","volume":"44","author":"Salunkhe","year":"2023","journal-title":"Neurolog. Sci."},{"key":"10.1016\/j.msard.2025.106402_bib0028","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/a-1863-1862","article-title":"Seroprevalence of MOG and AQP4 antibodies and outcomes in an Indian cohort of pediatric acquired demyelinating syndromes","volume":"53","author":"Sankhyan","year":"2022","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.msard.2025.106402_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.03.006","article-title":"Prolonged fever: an Atypical presentation in MOG antibody-associated disorders","volume":"122","author":"Udani","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0030","article-title":"Atypical myelin oligodendrocyte glycoprotein antibody disease presenting with isolated elevated intracranial pressure","volume":"1","author":"Valdrighi","year":"2021","journal-title":"Neuroimmunol. Rep."},{"key":"10.1016\/j.msard.2025.106402_bib0031","article-title":"Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease","author":"Virupakshaiah","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106402_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104879","article-title":"Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"77","author":"Wang","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106402_bib0033","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106402_bib0034","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106402_bib0035","first-page":"E35391","article-title":"Clinical characteristics and long-term follow-up outcomes of myelin oligodendrocyte glycoprotein antibody-associated disease in Han Chinese participants","volume":"102","author":"Zeng","year":"2023","journal-title":"Med. (U.S.)"},{"key":"10.1016\/j.msard.2025.106402_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2021.09.035","article-title":"Clinical characteristics, disease course, and outcomes of paediatric patients with myelin oligodendrocyte glycoprotein-Ab associated disease: a retrospective clinical study","volume":"94","author":"Zhang","year":"2021","journal-title":"J. Clin. Neurosci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:26:44Z","timestamp":1746620804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"alternative-id":["S2211034825001440"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106402","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinico-investigational profile, relapse predictors and outcomes of pediatric patients with anti-myelin oligodendrocyte associated disorders: An experience from tertiary centre","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106402"}}